Production (Stage)
Fennec Pharmaceuticals Inc.
FRX.TO
TSX
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 10.42% | 13.64% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 10.42% | 13.64% | |||
| Cost of Revenue | -44.25% | -50.70% | |||
| Gross Profit | 15.46% | 29.18% | |||
| SG&A Expenses | 11.70% | -24.08% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 7.90% | -27.24% | |||
| Operating Income | 13.49% | 82.05% | |||
| Income Before Tax | 28.09% | 71.75% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 41.31% | 65.39% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 41.31% | 65.39% | |||
| EBIT | 13.49% | 82.05% | |||
| EBITDA | 13.97% | 82.44% | |||
| EPS Basic | 41.63% | 65.49% | |||
| Normalized Basic EPS | 25.21% | 73.03% | |||
| EPS Diluted | 47.97% | 61.38% | |||
| Normalized Diluted EPS | 25.21% | 73.03% | |||
| Average Basic Shares Outstanding | 0.43% | 0.33% | |||
| Average Diluted Shares Outstanding | 0.43% | 0.33% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||